K. Berger, U.A. Ajani, C. S. Kase, J.M. Gaziano, J.E. Buring, R.J. Glynn, C.H. Hennekens: “Light-to-moderate alcohol consumption and the risk of stroke among U. S. Male phyicians”, New. Engl. J. Med., Vol. 341, (1999), pp. 1557–1567. http://dx.doi.org/10.1056/NEJM199911183412101 [CrossRef]
 J. Feher and A. Lugasi: “Antioxidant characteristics of a newly developed vermouth wine (Hung.)”, Orv Hetil., Vol. 145, (2004), pp. 2623–2627.
 C. S. Fuchs, M. J. Stampfer, G.A. Colditz, E.L. Giovannucci, J.E. Manson, I. Kawachi, D.J. Hunter, S.E. Hankinson, C.H. Hennekens and B. Rosner: “Alcohol consumption and mortality among women”, New Engl. J. Med., Vol. 332, (1995), pp. 1245–1250. http://dx.doi.org/10.1056/NEJM199505113321901 [CrossRef]
 J. M. Gaziano, J.E. Buring, J. L. Breslow, S.Z. Goldhaber, B. Rosner, M. VanDenburgh, W. Willett, C.H. Hennekens.: “Moderate alcohol intake increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction”, New Engl. J. Med., Vol. 329, (1993), pp. 1829–1834. http://dx.doi.org/10.1056/NEJM199312163292501 [CrossRef]
 R. Doll, R. Peto, E. Hall, K. Wheatley, R. Gray.: “Mortality in relation to consumption of alcohol: 13 years’ observations on male British doctors”, Brit. Med. J., Vol. 309, (1994), pp. 911–918.
 C.L. Hart, G. D. Smith, D. J. Hole, V. M. Hawthorne: “Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: results from a prospective cohort study of Scottsh men with 21 years of follow up”, Brit. Med. J., Vol. 318, (1999), pp. 1725–1729.
 R. D. Langer, M. H. Criqui, D. M. Reed: “Lipoproteins and blood pressure as biological pathways for effect of moderate alcohol consumption on coronary heart disease”, Circulation, Vol. 85, (1992), pp. 910–915.
 J.M. Leppälä, M. Paunio, J. Virtamo, R. Fogelholm, D. Albanes, P.R. Taylor, O.P. Heinonen: “Alcohol consumption and stroke incidence in male smokers”, Circulation, Vol. 100, (1999), pp. 1209–1214.
 M.J. Stampfer, G.A. Colditz, W.C. Willett, F.E. Speizer, C.H. Hennekens: “A propective study of moderate alcohol consumption and the risk of coronary disease and stroke in women”, New Engl. J. Med., Vol. 319, (1988), pp. 267–273. http://dx.doi.org/10.1056/NEJM198808043190503 [CrossRef]
 L. Szollár: The wine (Hung). Táplálkozás-Anyagcsere-Diéta, Vol.1, (1995), pp. 37–42.
 Magyar Gyógyszerkönyv (Hungarian Pharmacopeia) I. Pesti Könyvnyomda Rt. Budapest, (1871), pp. 465–473.
 A.S.St. Leger, A.L. Cochrane, F. Moore: “Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine”, Lancet, Vol. 1, (1979), pp. 1017–1020. http://dx.doi.org/10.1016/S0140-6736(79)92765-X [CrossRef]
 M. Law, N. Wald: “Why heart disease mortality is low in France: the time lag explanation”, Brit. Med. J., Vol.318, (1999), pp. 1471–1476.
 M.J. Stampfer, J. H. Kang, J. Chen, R. Cherry, F. Grodstein: “Effects of moderate alcohol consumption on cognitive function in women”, N Engl J Med, Vol. 352, (2005), pp. 245–253. http://dx.doi.org/10.1056/NEJMoa041152 [CrossRef]
 M. H. Criqui, B. A. Golomb: “Should patients with diabetes drink to to their health?”, JAMA, Vol. 282, (1999), pp. 279–280. http://dx.doi.org/10.1001/jama.282.3.279 [CrossRef]
 S.S. Hall: “Longevity research. In vino vitalis? Compounds activate life-extending genes”, Science, Vol. 30. (2003), pp. 1165. http://dx.doi.org/10.1126/science.301.5637.1165 [CrossRef]
 M. Marmot, E. Brunner: “Alcohol and cardiovasc disease: the status of th U shaped curve”, Brit. Med. J., Vol. 303, (1991), pp. 565–568. http://dx.doi.org/10.1136/bmj.303.6802.565 [CrossRef]
 T.J. Regan: “Moderate alcohol consumption and risk of coronary heart disease among women with type 2 diabetes mellitus”, Circulation, Vol. 102, (2000), pp. 487–488.
 P. McElduff, A.J. Dobson: “How much alcohol and how often? Population based case-control study of alcohol consumption and risk of a major coronary event”, Brit. Med. J., Vol. 314, (1997), pp. 1159–1154.
 K. J. Mukamal, W.T. Longstreth, M.A. Mittleman R.M. Crum, D.S. Siscovick: “Alcohol consumption and subclinical findings on magnetic resonance imaging the brain in older adults: the cardiovascular health study”, Stroke, Vol. 32, (2001), pp. 1939–1946.
 S.W. Nigdikar, N. R. Williams, B. A. Griffin, A. N. Howard: “Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo”, Am. J. Clin. Nutr., Vol. 68. (1998), pp. 258–265.
 R. L. Sacco, M. Elkind, B. Boden-Albala, I. F. Lin, D. E. Kargman, W. A. Hauser, S. Shea, M.C. Paik: “The protective effect of moderate alcohol consumption on ischemic stroke”, JAMA, Vol. 281. (1999), pp. 53–60. http://dx.doi.org/10.1001/jama.281.1.53 [CrossRef]
 C. G. Solomon, F. B. Hu, M. J. Stampfer, G. A. Colditz, F. E. Speizer, E. B. Rimm, W. C. Willett, J.E. Manson: “Moderate alcohol consumption and risk of coronary heart disease among women with type 2 diabetes mellitus”, Circulation, Vol. 102. (2000), pp. 494–499.
 M. J. Stampfer, G. A. Colditz, W. C. Willett, J. E. Manson, R. A. Arky, C. H. Hennekens, F. E. Speizer: “A prospective study of moderate alcohol drinking and risk of diabetes in women”, Am J Epidemiol., Vol. 128, (1988), pp. 549–558.
 R.D. Langer, M.H. Criqui, D.M. Reed: “Lipoproteins and blood pressure as biological pathways for effect of moderate alcohol consumption on coronary heart disease”, Circulation, Vol. 85. (1992), pp. 910–915.
 A. A. Lorimier: “Alcohol, wine, and health”, Am. J. Surg., Vol. 180. (2000), pp. 357–361 http://dx.doi.org/10.1016/S0002-9610(00)00486-4 [CrossRef]
 A. Lugasi, A. Blázsovics, E. Dworschák, J. Fehér: “The cardioprotective effects of red wines according to the literature (Hung.)”, Orv. Hetil., Vol. 138. (1997), pp. 673–678
 E.B. Rimm, A. Klatsky, D. Grobbee, M.J Stampfer: “Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits?”, Brit. Med. J., Vol. 312. (1996), pp. 731–736.
 M. M. Thun, R. Peto, A. D. Lopez, J. H. Monaco, S. J. Henley, C. W. Jr. Heath, R.. Doll: “Alcohol consumption and mortality among middle-aged and elderly U.S. adults”, New Engl. J. Med., Vol. 337. (1997), pp. 1705–1714. http://dx.doi.org/10.1056/NEJM199712113372401 [CrossRef]
 M. Trevisan, E. Schisterman, A. Mennotti, G. Farchi, S. Conti: “Drinkind pattern and mortality: the Italian Risk Factor and Life Expectancy pooling project”, Ann. Epidemiol., Vol. 11, (2001), pp. 312–319. http://dx.doi.org/10.1016/S1047-2797(00)00183-6 [CrossRef]
 C. T. Valmadrid, R. Klein, S. E. Moss, B. E. Klein, K. J. Cruickshanks: “Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus”, JAMA, Vol. 282. (1999), pp. 239–246. http://dx.doi.org/10.1001/jama.282.3.239 [CrossRef]
 M. H. Criqui, B. L. Ringel: “Does diet alcohol explain the French paradox?”, Lancet, Vol. 344, (1994), pp. 1719–1723. http://dx.doi.org/10.1016/S0140-6736(94)92883-5 [CrossRef]
 A, Lugasi, A. Blazovics, J. Feher: “In vitro findings of antioxidant properties of Hungarian red wines (Hungarian)”, Orv Hetil., Vol. 140, (1999), 2051–2056.
 S. Renaud, M. de Lorgeril: “Wine, alcohol, platelets, and French paradox for coronary heart disease”, Lancet, Vol. 339, (1992), pp. 1523–1526. http://dx.doi.org/10.1016/0140-6736(92)91277-F [CrossRef]
 J. Belleville: “The French paradox: possible involvement of ethanol in the protective effect against cardiovascular diseases”, Nutrition, Vol. 18, (2002), pp. 173–177. http://dx.doi.org/10.1016/S0899-9007(01)00721-3 [CrossRef]
 L. Szollár: “Pathophysiology of Metabolism”, In: Kórélettan (Pathophysiology), Ed.: L. Szollár, Semmelweis Publishing House, Budapest, 1993. pp. 156–224.
 A. A. Lorimier: “Alcohol, wine, and health”, Am. J. Surg., Vol. 180, (2000), pp. 357–361. http://dx.doi.org/10.1016/S0002-9610(00)00486-4 [CrossRef]
 A. M. Malarcher, W. H. Giles, J. B. Croft, M. A.Wozniak, R. J. Wityk, P. D. Stolley, B. J. Stern, M. A. Sloan, R. Sherwin, T. R. Price, R. F. Macko, C. J. Johnson, C. J. Earley, D. W. Buchholz, S. J. Kittner: “Alcohol intake, type of beverage, and the risk of cerebral infarction in young women”, Stroke, Vol. 32 (2001), pp. 77–83. [CrossRef]
 J. Vina, C. Borras, J. Gambini, J. Sastre, F. V. Pallardo: “Why females live longer than males: control of longevity by sex hormones”, Sci Aging Knowledge Environ., Vol. 23, (2005), pp. 2005–2022.
 A. P. Whelan, W. H. Sutherland, M. P. McCormick, D. J. Yeoman, S. A. de Jong, M. J. Williams: “Effects of white and red wine on endothelial function in subjects with coronary artery disease”, Intern Med J., Vol. 34, (2004), pp. 224–228. http://dx.doi.org/10.1111/j.1444-0903.2004.00507.x [CrossRef]
 E. B. Rimm, J. Chan, M. J. Stampfer: “Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men”, Brit. Med. J., Vol. 310, (1995), pp. 555–559.
 M. de Lorgeril, P. Salen, F. Boucher, J. de Leiris, F. Paillard: “Effect of wine ethanol on serum iron and ferritin levels in patients with coronary heart disease”, Nutr. Metab.Cardiovasc. Dis., Vol. 11. (2001), pp. 176–180.
 Y. Miyagi, K. Miwa, H, Inoue: “Inhibition of human low-density lipoprotein oxidation by flavonoids in red wine and grape juice”, Am J Cardiol., Vol. 80. (1997), pp. 1627–1631 http://dx.doi.org/10.1016/S0002-9149(97)00755-8 [CrossRef]
 E. N. Frankel, A. L. Waterhouse, J. E. Kinsella: “Inhibition of human LDL oxidation by resveratrol”, Lancet, Vol. 341. (1993), pp. 1103–1104. http://dx.doi.org/10.1016/0140-6736(93)92472-6 [CrossRef]
 S. Maxwell, A. Cruickshank, G. Thorpe: “Red wine and antioxidant activity in serum”, Lancet, Vol. 344, (1994), pp. 193–194. http://dx.doi.org/10.1016/S0140-6736(94)92795-2 [CrossRef]
 A. Par, E. Roth, Gy. Rumi, Z. Kovacs, J. Nemes, G. Mozsik: “Oxidative stress and antioxidant protection in alcoholic liver disease and in chronic hepatitis C (Hung.)”, Orvosi Hetilap, Vol. 144. (2000), pp. 1655–1660
 S. C. Renaud, J-C. Ruf: “Effects of alcohol on platelet functions”, Clin. Chim. Acta, Vol. 246, (1996), pp. 77–89. http://dx.doi.org/10.1016/0009-8981(96)06228-6 [CrossRef]
 A. Blázovics, E. Fehér, J Fehér: “Role of free radical reactions in experimental hyperlipidemia in the pathomechanism of fatty liver”, In Free radicals and liver ed. Csomós, G., Fehér, J.: Springer Verlag, Berlin, 1992, pp. 96–123.
 K. Hagymasi, A. Blazovics, J. Feher, A. Lugasi, S. T. Kristo, A Kery: “The in vitro effect of dandelions antioxidants on microsomal lipid peroxidation”, Phytother Res., Vol. 14, (2000), pp. 43–44. http://dx.doi.org/10.1002/(SICI)1099-1573(200002)14:1<43::AID-PTR522>3.0.CO;2-Q [CrossRef]
 C. A. Camargo, P. T. Jr., Williams, K. M. Vranizan, J. J. Albers, P. D. Wood: “The effect of moderate alcohol intake on serum apolipoprotein A-I and A-II”, JAMA, Vol. 253, (1985), pp. 2854–2857. http://dx.doi.org/10.1001/jama.253.19.2854 [CrossRef]
 K. Hagymasi, A. Blazovics, G. Lengyel, I. Kocsis, J. Feher: “Oxidative damage in alcoholic liver disease”, Eur J Gastroenterol Hepatol., Vol. 13. (2001), pp. 49–53. http://dx.doi.org/10.1097/00042737-200101000-00009 [CrossRef]
 A. Lugasi: “Potencial health protective effects of food flavonoids (Hung.)”, Orvosi Hetilap, Vol. 241, (2000), pp. 1751–1760.
 S. Renaud, D. Lanzmann-Petithory: “Coronary heart disease: dietary links and pathogenesis”, Publ. Health Nutr., Vol. 4, (2001), pp. 459–474.
 J. Fehér, D. Drexler: “Polyphenols in wine (Hung.)”, Borbar?at (Friends of Wine), Vol. 6, (2001), pp. 56–58.
 A. Lugasi, A. Blázovics, E. Dworschak J. Fehér: “Cardio-protective effect of red wine as reflected in the literature (Hungarian)”, Orv Hetil., Vol. 138, (1997), pp. 673–678.
 T. Nakayama: “Suppression of hydroperoxide-induced cytotoxicity by polyphenols”, Cancer Res., Vol. 54, (1994), pp. 1191–1193S.
 C. R. Pace-Asciak, S. Hahn, E. P. Diamandis, G. Soleas, D. M. Goldberg: “The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease”, Clin. Chim. Acta, Vol. 235, (1995) pp. 207–219 http://dx.doi.org/10.1016/0009-8981(95)06045-1 [CrossRef]
 L. H. Opie, S. Lecour: “The red wine hypothesis: from concepts to protective signalling molecules”, European. Heart Journal, Vol. 28, (2007), pp. 1683–1693 http://dx.doi.org/10.1093/eurheartj/ehm149 [CrossRef]
 S. Das, A. Tosaki, D. Bagchi, N. Maulik, D. K. Das: “Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptor by Aktdependent and-independent pathways”, J Pharmacol Exp Ther, Vol. 314, (2005), pp. 762–769. http://dx.doi.org/10.1124/jpet.105.084285
 U. G. Haider, T. U. Roos, M. I. Kontaridis, B. G. Neel, D. Sorescu, K. K. Griendling, A. M. Vollmar, V. M. Dirsch: “Resveratrol inhibits angiotensin II-and epidermal growth factor-mediated Akt activation: role of Gab1 and Shp2”, Mol Pharmacol, Vol. 68, (2005), pp. 41–48.
 G. Stef, A. Csiszar, K. Lerea, Z. Ungvari, G. Veress: “Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance”, J Cardiovasc Pharmacol, Vol. 48, (2006), pp. 1–5. http://dx.doi.org/10.1097/01.fjc.0000238592.67191.ab [CrossRef]
 A. Csiszar, K. Smith, N. Labinskyy, Z. Orosz, A. Rivera, Z. Ungvari: “Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition”, Am J Physiol Heart Circ Physiol, Vol. 291, (2006), pp. H1694–H1699. http://dx.doi.org/10.1152/ajpheart.00340.2006 [CrossRef]
 T.L. Zern and M.L. Fernandez: “Cardioprotective Effects of Dietary Polyphenols”, J. Nutr. Vol., Vol. 135, (2005), pp. 2291–2294.
 O.H. Franco, L. Bonneux, C. de Laet, A. Peeters, E. W. Steyerberg and J.P. Mackenbach: “The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75%”, Brit. Med. J. Vol., Vol. 329, (2004), pp. 1447–1450. http://dx.doi.org/10.1136/bmj.329.7480.1447 [CrossRef]
 J. Feher and A. Lugasi: “Antioxidant characteristics of a newly developed vermouth wine? (Hung.)”, Orv Hetil., Vol. 145, (2004), pp. 2623–2627.
formerly Central European Journal of Medicine
IMPACT FACTOR increased in 2015: 0.190
5-year IMPACT FACTOR: 0.221
SCImago Journal Rank (SJR) 2015: 0.140
Source Normalized Impact per Paper (SNIP) 2015: 0.154
Impact per Publication (IPP) 2015: 0.197
The cultural history of wine - theoretical background to wine therapy
1II. Department of Medicine, Semmelweis University, Budapest, Hungary
2National Institute of Food Safety and Nutrition Science, Budapest, Hungary
© 2007 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. (CC BY-NC-ND 3.0)
Citation Information: Open Medicine. Volume 2, Issue 4, Pages 379–391, ISSN (Online) 2391-5463, DOI: 10.2478/s11536-007-0048-9, December 2007
- Published Online:
The knowledge of grape and wine is as old as the cultural history of mankind. Moderate consumption of wine can be beneficial in healthy individuals. It is also known from ancient times that it can cause acute and chronic damage when consumed in great quantities. The disinfectant effect of its use in ointments has been observed already in the antiquity. Polyphenols, among them resveratrol, have generated a great amount of scientific research due to their in vivo and in vitro antioxidant capabilities. For decades, red wine was thought to have beneficial effects on cardiovascular health. This relation was clearly established in the French Paradox phenomenon as well as in the Mediterranean diet. The French Paradox is defined as a low incidence of coronary heart disease, while consuming a diet rich in saturated fat. The cause of this phenomenon is the usually wine drinking in small quantity, supposingly in the consequence of polypenols in red wine. The use of ointments containing polyphenols of wine and the cosmetic treatments with them can be advantageous in the treatment and prevention of some diseases of the skin and the joints, due to its free radical scavenging effect. In healthy individuals the consumption of a moderate amount of 1 to 2 dl wine a day may reduce the mortality of cardiovascular diseases. However, also this quantity can be associated with detrimental effects in pregnant women, in children and in patients with various organic, particularly hepatic, diseases as well as in case of regular administration of certain medicines.